AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Thermo Fisher Scientific's Oncomine Dx Target Test Gains FDA Approval for NSCLC Treatment.
ByAinvest
Tuesday, Aug 12, 2025 1:41 pm ET1min read
Thermo Fisher Scientific's Oncomine Dx Target Test has gained FDA approval as a companion diagnostic for HERNEXEOS, contributing to a 7.8% price increase over the last quarter. The company's growth aligns with broader market trends, with the S&P 500 and Nasdaq hitting all-time highs following positive inflation data. Analysts forecast annual revenue growth of 4.8% and earnings reaching $8.9 billion by 2028. The current share price of $462.39 remains below the consensus price target of $550.28, suggesting potential upside.
Thermo Fisher Scientific (TMO) has seen a significant boost following the recent FDA approval of its Oncomine Dx Target Test as a companion diagnostic for HERNEXEOS. The test, which identifies patients with human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations in non-small cell lung cancer (NSCLC) tumors, has contributed to a 7.8% price increase over the last quarter [2].The FDA approval aligns with broader market trends, with the S&P 500 and Nasdaq hitting all-time highs following positive inflation data. This approval positions Thermo Fisher Scientific favorably within the precision medicine sector, emphasizing its capability in developing innovative diagnostic tools and potential revenue streams in the growing biotech and pharmaceutical sectors [1].
The company's growth narrative is supported by analysts forecasting annual revenue growth of 4.8% and anticipating earnings reaching US$8.9 billion by 2028. Despite these projections, the current share price of US$462.39 remains below the consensus price target of US$550.28, suggesting potential upside [2].
The approval of the Oncomine Dx Target Test and subsequent product launches could enhance revenue and earnings forecasts, bolstering confidence in Thermo Fisher Scientific's growth trajectory. However, the company's recent performance has seen it underperform the broader US market's 19.4% gain over the past year, highlighting some challenges amid a shifting macroeconomic environment [2].
References:
[1] https://www.biospectrumasia.com/news/104/26481/thermo-fisher-receives-us-fda-approval-for-ngs-based-oncomine-dx-target-test-as-companion-diagnostic.html
[2] https://sg.finance.yahoo.com/news/thermo-fisher-scientific-tmo-oncomine-172801916.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet